Partitioned blood pressure polygenic risk reveals differential genetic effects of tissue-specific enhancers and their interactions on cardiovascular disease
This study introduces a framework that decomposes blood pressure polygenic risk scores into tissue-specific components, revealing that context-dependent genetic effects and gene-environment interactions (such as ATP2B1's response to medication) significantly influence cardiovascular disease risk and improve prediction accuracy compared to traditional aggregate scores.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
For decades, scientists have tried to predict who might develop complex conditions like high blood pressure by looking at a person's entire genetic code. They developed a tool called a polygenic risk score, which acts like a single number summarizing the tiny effects of millions of genetic variations. The idea was simple: add up all the small risks, and you get a clear picture of a person's future health. However, this approach treats the genome as a single, uniform block, ignoring the fact that different parts of our DNA are active in different organs. A gene might be busy working in the heart but silent in the kidney, yet the old method counted them all the same. This lack of detail meant that while the scores could predict risk, they could not explain why that risk existed or how it might change based on a person's environment, such as the medications they take or their age.
A team of researchers has now introduced a new way to look at these genetic scores, one that breaks the single number apart to see the distinct biological machinery behind it. Instead of treating the genome as one big lump, they sorted the genetic variations based on where they are active in the body. They focused on four key organs involved in blood pressure: the adrenal glands, arteries, heart, and kidneys. By separating the genetic signals into these specific tissue groups, they discovered that the old, single-number score was hiding a complex reality. The genetic factors driving blood pressure do not act the same way everywhere; they interact with a person's life in different ways depending on which organ they are influencing.
The researchers applied this new method to data from hundreds of thousands of people, analyzing millions of genetic variations. They found that when they looked at the genetic score as a whole, it seemed to work consistently. But when they split that score into its tissue-specific parts, the results were surprisingly different. The genetic signals from the arteries behaved differently than those from the kidneys, and these differences were not random. The study showed that these tissue-specific scores interact with the environment in powerful ways. For instance, the genetic risk coming from the kidneys was found to change significantly depending on a person's age and whether they were taking medication for high blood pressure. This suggests that the reason a genetic risk score might fail to predict an outcome in some people is not because the score is wrong, but because it is missing the context of how those genes are actually being used in the body.
One of the most striking findings involved a specific genetic variation located in a region of DNA active only in the kidneys. In the general population, this variation was linked to a higher risk of high blood pressure. However, when the researchers looked at people who were already taking medication to lower their blood pressure, this same genetic variation acted as a shield, protecting them from heart disease and heart attacks. This protective effect was invisible when looking at the total genetic score because the risk and the protection were canceling each other out. By separating the signals, the researchers could see that for patients on medication, having this specific kidney-related genetic profile meant they responded better to treatment. This discovery highlights that a person's genetic risk is not a fixed destiny but a dynamic potential that shifts based on their medical history and environment.
The study also revealed that different parts of the body contribute to blood pressure in unique ways. While some genetic factors seemed to affect the whole system, others were highly specific. For example, a gene called ADAMTS8 was found to have opposite effects on different components of blood pressure: it raised the lower number (diastolic pressure) while lowering the upper number (systolic pressure). In the old way of calculating risk, these opposing forces would have made the gene look harmless or unimportant. But by separating the signals, the researchers could see that this gene was actively reshaping how blood flows through the arteries, increasing flexibility in large vessels while tightening smaller ones. This level of detail allows scientists to move beyond simple prediction and start understanding the specific biological pathways that lead to disease.
The researchers tested their findings in a separate group of people to ensure the results were real and not just a fluke of the first group. The patterns held up, confirming that the interactions between tissue-specific genes and environmental factors are a fundamental part of how blood pressure works. They also showed that using this new, split-up approach improved the ability to predict blood pressure levels compared to the old, single-number method. This improvement was seen even when looking at people from different ancestral backgrounds, suggesting that this method could help make genetic predictions more accurate for everyone, not just those of European descent.
Ultimately, this work suggests that the future of genetic medicine lies in looking at the details rather than the summary. The old polygenic risk score was like a weather forecast that only gave the average temperature for a whole country, missing the fact that it was raining in the mountains and sunny at the coast. By breaking the score down into its tissue-specific parts, researchers can now see the local weather. They can identify which genes are active in which organs, how they interact with a person's lifestyle and medications, and why some people respond to treatment while others do not. This shift from a blunt, aggregate tool to a precise, mechanistic probe offers a new path toward personalized medicine, where treatments can be tailored not just to a person's genes, but to the specific biological context in which those genes are operating.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.